Hot Features
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF wi... Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development. It also develops Torudokimab (ZB-880), a fully human immunoglobulin G4 monoclonal antibody targeting interleukin-33 that has completed Phase 1 clinical studies; and Crebankitug (ZB-168), a fully human immunoglobulin G1 monoclonal antibody targeting interleukin-7 receptor alpha that has completed Phase 1 clinical studies. Zura Bio Limited was founded in 2022 and is headquartered in Henderson, Nevada. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.775 | 18.1924882629 | 4.26 | 6.01 | 4.26 | 3562921 | 5.38265068 | CS |
| 4 | 1.175 | 30.4404145078 | 3.86 | 6.01 | 3.25 | 1835671 | 4.55978697 | CS |
| 12 | -0.635 | -11.1992945326 | 5.67 | 6.01 | 3.25 | 1042314 | 4.69414795 | CS |
| 26 | -0.205 | -3.91221374046 | 5.24 | 7.44 | 3.25 | 844037 | 5.24510815 | CS |
| 52 | 3.975 | 375 | 1.06 | 7.44 | 1.06 | 988958 | 4.17181973 | CS |
| 156 | -3.215 | -38.9696969697 | 8.25 | 8.31 | 0.97 | 549858 | 3.7221799 | CS |
| 260 | -2.965 | -37.0625 | 8 | 37.55 | 0.97 | 567061 | 4.50259575 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.